Land: New Zealand
Sprog: engelsk
Kilde: Medsafe (Medicines Safety Authority)
Conjugated estrogens 1.25mg;
Wyeth (NZ) Ltd
Conjugated estrogens 1.25 mg
1.25 mg
Tablet
Active: Conjugated estrogens 1.25mg Excipient: Calcium sulfate Carnauba wax Glyceryl mono-oleate Ink Lactose monohydrate Macrogol 20000 Magnesium stearate Methylcellulose Microcrystalline cellulose Quinoline yellow Shellac Stearic acid Sucrose Sunset yellow FCF Titanium dioxide
Blister pack, 28 tablets, 28 tablets
Prescription
Prescription
Wyeth Pharmaceuticals Inc
Package - Contents - Shelf Life: Blister pack, 28 tablets - 28 tablets - 36 months from date of manufacture stored at or below 30°C - Blister pack, 3 x 28 tablets - 84 tablets - 36 months from date of manufacture stored at or below 30°C - Bottle, plastic, HDPE - 60 tablets - 36 months from date of manufacture stored at or below 30°C
1969-12-31
Version: pfdpremt10119 Supersedes: pfdpremt10716 Page 1 of 18 NEW ZEALAND DATA SHEET 1. PRODUCT NAME Premarin ® 0.3 mg, 0.625 mg tablets. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each Premarin tablet contains 0.3 mg or 0.625 mg conjugated estrogens. Conjugated estrogens (CE) is a mixture of natural estrogens (of equine origin) composed principally of the sodium salts of water soluble sulfate esters of estrone, equilin, and 17 alpha-dihydroequilin, together with smaller amounts of 17 alpha-estradiol, equilenin, and 17 alpha-dihydroequilenin, 17 beta-dihydroequilin, 17 beta-dihydroequilenin, 17 beta-estradiol and delta 8, 9-dihydroestrone. EXCIPIENT(S) WITH KNOWN EFFECT Each Premarin 0.3 mg tablet contains 61.7 mg lactose monohydrate and 45 mgsucrose. Each Premarin 0.625 tablet contains 54.1 mg lactose monohydrate and 45 mg sucrose. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet. Premarin 0.3 mg tablet is dark green, oval biconvex sugar-coated and marked with “0.3 ” in white ink. Premarin 0.625 tablet is maroon, oval biconvex sugar-coated and marked with “ 0.625 ” in white ink. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Estrogens with or without progestogens should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman. Premarin is indicated: AS REPLACEMENT THERAPY FOR ESTROGEN DEFICIENCY STATES ASSOCIATED WITH CLIMACTERIC MANIFESTED BY: • moderate to severe vasomotor symptoms associated with the estrogen deficiency in natural and surgical menopause (sweating, hot flushes). Version: pfdpremt10119 Supersedes: pfdpremt10716 Page 2 of 18 • atrophic vaginitis due to menopause. When prescribing solely for the treatment of symptoms of vaginal atrophy, topical vaginal products should be considered. There is no evidence that estrogens are effective for anxiety or depression without associated vasomotor symptoms, and they should not be used to treat such conditions. FOR THE PREVENTI Læs hele dokumentet